[November 16, 2022, Shanghai] Today, the 2022 Interface Healthcare Forum, themed "Walking the Path of Goodness, Health Everlasting," officially convened in Shanghai. The annual ceremony of the "2022 Everlasting Award" was also grandly unveiled during this conference. TECNIS Symfony® Extended Range of Vision Intraocular Lens, the world's first extended range of vision intraocular lens from Johnson & Johnson Vision, successfully won the 2022 Everlasting Award for Popular Intraocular Lens of the Year thanks to its superior product technology and excellent visual quality experience.
As a medical and health forum hosted by Shanghai United Media Group | Interface News, the Interface Great Health Forum, with the theme of "Walking Towards Goodness, Health Everlasting," brought together an expert lineup of domestic scholars and industry experts to share and discuss the overall development trends and cutting-edge issues in China's great health industry. The forum also announced the final list of winners for the 2022 Evergreen Awards, aiming to recognize outstanding companies in the great health sector—including pharmaceuticals, medical devices, drug sales, medical services, and health management—for their relentless drive and innovative spirit in advancing human health.
The conference specially invited well-known media professionals, editors, and reporters from dozens of fields, as well as renowned data agencies, consulting firms, and other parties to participate in the award selection. The evaluation comprehensively assessed the healthcare industry from multiple dimensions such as innovation, brand reputation, and accessibility. Ultimately, 30 leading companies or innovative products in the industry were voted to win the awards. At the 2022 Changchun Awards ceremony, TECNIS Symfony® Toric Continuous Vision Intraocular Lens, as the world's first continuous vision intraocular lens and currently the only EDOF intraocular lens in China, successfully claimed the 2022 Changchun Award and won the "Most Popular Crystal of the Year" award. This was achieved thanks to its outstanding performance, including Echelette diffraction grating technology, Achromatic active achromatization, minimizing total ocular chromatic aberration, improving patients' visual quality, and restoring a truly natural visual experience for patients.
"It is a great honor to see our TECNIS Symfony® Continuous Vision Lens awarded the 2022 Evergreen Award for 'Most Popular Lens of the Year'." Said Wang Liping, Vice President of Johnson & Johnson Vision in Greater China, Australia, and New Zealand: "For years, multifocal intraocular lenses have overcome the limitations of traditional monofocal intraocular lenses in near vision, providing patients with excellent distance and near vision. With the development and introduction of groundbreaking extended depth-of-focus intraocular lenses, patients can now enjoy high-quality, complete, and continuous dynamic vision. Refractive cataract surgery has gained better options and broader development opportunities thanks to advancements in intraocular lens technology. In the future, Johnson & Johnson Vision will continue to focus on addressing more diverse needs of cataract patients and benefiting more individuals in China through innovative technologies and products. We are committed to empowering the development of refractive cataract surgery in China and contributing to the grand goal of building a healthier China."
As a global leader in the healthcare industry, Johnson & Johnson has long been committed to bringing globally innovative technologies, solutions, and advanced manufacturing experience to China, helping people see more clearly, communicate more effectively, and live better lives. In the future, guided by Johnson & Johnson's Credo, Johnson & Johnson Vision will continue to invest in the research and development of innovative medical technologies, accelerate the expansion of high-quality ophthalmic medical resources, and ensure that internationally leading technologies and innovative products in the field of ophthalmic clinical treatment better serve Chinese patients, contributing to the construction of a Healthy China.